Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Monday, March 8

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

Sep 23, 2020 12:53am EDT

CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

Sep 20, 2020 9:14pm EDT

CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing

Sep 10, 2020 4:50pm EDT

U.K. MHRA Grants Meeting to CytoDyn to Discuss Fast Track Approval of Leronlimab for COVID-19 Patients

Sep 02, 2020 4:01pm EDT

Global Health Leaders Join CytoDyn's Scientific Advisory Board

Sep 01, 2020 6:00am EDT

CytoDyn to Hold Conference Call on September 2 to Provide Update on Timelines for Multiple Regulatory and Clinical Initiatives Including COVID-19 Potential Approvals

Aug 28, 2020 4:37pm EDT

CytoDyn Reaches Enrollment of 195 Patients in its Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

Aug 25, 2020 8:48pm EDT

After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

Aug 20, 2020 4:51am EDT

To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4

Aug 20, 2020 3:36am EDT

CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors

Aug 19, 2020 2:44am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap